TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy
Brief Summary: The study is designed to answer the question: will nicotine at doses that do not cause serious side effects, show feasibility in treatment of levodopa-induced dyskinesia in patients with Parkinson's disease?


Options:
A: Arm Label: Nicotine; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo comparator | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Nicotine | Intervention Type: OTHER; Name: placebo comparator; Assigned to Arm(s): placebo
B: Arm Label: ADS-5102 (amantadine HCl extended release); Type: EXPERIMENTAL; Interventions: Drug: ADS-5102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: ADS-5102; Assigned to Arm(s): ADS-5102 (amantadine HCl extended release) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi | Arm Label: B. Strength training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Strength training | Arm Label: C. Low-Impact; Type: OTHER; Interventions: Behavioral: Low-Impact Exercise Control | Intervention Type: BEHAVIORAL; Name: Tai Chi; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): B. Strength training | Intervention Type: BEHAVIORAL; Name: Low-Impact Exercise Control; Assigned to Arm(s): C. Low-Impact
D: Arm Label: IPX066; Type: EXPERIMENTAL; Interventions: Drug: IPX066, Drug: IR CD-LD | Arm Label: IR CD-LD; Type: ACTIVE_COMPARATOR; Interventions: Drug: IPX066, Drug: IR CD-LD | Intervention Type: DRUG; Name: IPX066; Assigned to Arm(s): IPX066, IR CD-LD | Intervention Type: DRUG; Name: IR CD-LD; Assigned to Arm(s): IPX066, IR CD-LD

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults Aged 18 Years and Older
Brief Summary: The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults


Options:
A: Arm Label: Influenza vaccine; Type: EXPERIMENTAL; Interventions: Biological: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Phosphate buffered saline | Intervention Type: BIOLOGICAL; Name: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived); Assigned to Arm(s): Influenza vaccine | Intervention Type: OTHER; Name: Phosphate buffered saline; Assigned to Arm(s): Placebo
B: Arm Label: Trivalent Influenza vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent influenza vaccine | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline | Intervention Type: BIOLOGICAL; Name: Trivalent influenza vaccine; Assigned to Arm(s): Trivalent Influenza vaccine | Intervention Type: BIOLOGICAL; Name: Normal saline; Assigned to Arm(s): Normal saline
C: Arm Label: CSL425 (7.5 mcg); Type: EXPERIMENTAL; Interventions: Biological: CSL425 | Arm Label: CSL425 (15 mcg); Type: EXPERIMENTAL; Interventions: Biological: CSL425 | Arm Label: CSL425 (30 mcg); Type: EXPERIMENTAL; Interventions: Biological: CSL425 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: CSL425; Assigned to Arm(s): CSL425 (7.5 mcg) | Intervention Type: BIOLOGICAL; Name: CSL425; Assigned to Arm(s): CSL425 (15 mcg), CSL425 (30 mcg) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: CCI; Type: EXPERIMENTAL; Interventions: Biological: Cell culture-derived influenza vaccine | Arm Label: IVV; Type: EXPERIMENTAL; Interventions: Biological: Egg-derived influenza virus vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Cell culture-derived influenza vaccine; Assigned to Arm(s): CCI | Intervention Type: BIOLOGICAL; Name: Egg-derived influenza virus vaccine; Assigned to Arm(s): IVV | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled, Single-center Study of the Efficacy and Safety of BIO-K+ CL-1285® in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Bio-K+ CL-1285 in the prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridum difficile-Associated Diarrhea (CDAD) in hospitalized patients exposed to nosocomial infection.


Options:
A: Intervention Type: OTHER; Name: Biventricular pacing post cardiac surgery; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Kefir; Type: EXPERIMENTAL; Interventions: Other: Kefir | Intervention Type: OTHER; Name: Kefir; Assigned to Arm(s): Kefir | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Saccharomyces boulardii; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saccharomyces boulardii | Arm Label: Microcristallin cellulose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Microcristallin cellulose
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: BIO-K+ CL-1285; Type: ACTIVE_COMPARATOR; Interventions: Other: BIO-K+ CL-1285® | Arm Label: BIO-K+ CL-1285® & placebo; Type: OTHER; Interventions: Other: BIO-K+ CL-1285®, Other: Placebo | Intervention Type: OTHER; Name: BIO-K+ CL-1285®; Assigned to Arm(s): BIO-K+ CL-1285, BIO-K+ CL-1285® & placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): BIO-K+ CL-1285® & placebo, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VA Low Vision Intervention Trial (LOVIT) II
Brief Summary: This study will determine if the interdisciplinary team low vision rehabilitation program is more effective than basic low vision care provided by an optometrist working alone in improving visual reading ability in veterans with macular diseases and best corrected visual acuity of 20/50 to 20/200.


Options:
A: Arm Label: regular O&M-training; Type: ACTIVE_COMPARATOR; Interventions: Other: orientation and mobility training | Arm Label: standardised O&M-training; Type: EXPERIMENTAL; Interventions: Other: orientation and mobility training | Intervention Type: OTHER; Name: orientation and mobility training; Assigned to Arm(s): regular O&M-training, standardised O&M-training
B: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
C: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: Interdisciplinary Low Vision Service | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Basic Low Vision Service | Intervention Type: OTHER; Name: Interdisciplinary Low Vision Service; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Basic Low Vision Service; Assigned to Arm(s): Arm 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-blinded Single-site Control Study Comparing Blood Loss Prevention of Tranexamic Acid (TXA) to Epsilon Aminocaproic Acid (EACA) for Corrective Spinal Surgery
Brief Summary: Tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) have been reported to reduce blood loss in the cardiac surgery literature but they have not been reported in use head-to-head in the orthopedic surgery literature. In a randomized, double-blind, prospective study we believe that TXA will be more effective than both EACA and placebo at reducing blood loss for corrective spinal surgery.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid (Exacyl) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic acid (Exacyl); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Arm Label: Tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Epsilon Aminocaproic Acid; Type: EXPERIMENTAL; Interventions: Drug: Epsilon aminocaproic acid | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): Normal Saline | Intervention Type: DRUG; Name: Epsilon aminocaproic acid; Assigned to Arm(s): Epsilon Aminocaproic Acid
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Epsilon-Aminocaproic Acid (EACA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Epsilon-Aminocaproic Acid (EACA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: aprotinin or tranexamic acid; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Stroke Family Caregiver Support Across the Care Continuum by Improving the Timing of Intervention Delivery
Brief Summary: About 50% of stroke survivors have limitations in their activities of daily living on return to the community. Family caregivers provide invaluable support to these individuals during their recovery and rehabilitation. Unfortunately, there is no standard clinical practice to prepare caregivers for this role and, as a result, many experience stress and poor health that can compromise stroke survivor recovery and threaten the sustainability of the care needed to thrive in their home. To address this gap, the investigators have developed the Timing it Right Stroke Family Support Program that aims to meet the evolving needs of caregivers. The objective of this multi-province randomized controlled trial is to determine if this program delivered across the stroke care continuum improves caregivers' sense of being supported and emotional well-being. Ultimately this program could be used by stroke care programs from across Canada.


Options:
A: Arm Label: mod. Constraint-Induced Movement Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: mod. Constraint-Induced Movement Therapy | Arm Label: Therapy as usual; Type: OTHER; Interventions: Other: Therapy as usual | Intervention Type: BEHAVIORAL; Name: mod. Constraint-Induced Movement Therapy; Assigned to Arm(s): mod. Constraint-Induced Movement Therapy | Intervention Type: OTHER; Name: Therapy as usual; Assigned to Arm(s): Therapy as usual
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Family Mediated Exercise Therapy | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Family Mediated Exercise Therapy; Assigned to Arm(s): 1
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Tele-Rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Tele-rehabilitation | Intervention Type: OTHER; Name: Tele-rehabilitation; Assigned to Arm(s): Tele-Rehabilitation
D: Arm Label: Self-Directed Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-directed program | Arm Label: Stroke Support Person; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Timing it Right Stroke Family Support Person Intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Timing it Right Stroke Family Support Person Intervention; Assigned to Arm(s): Stroke Support Person | Intervention Type: BEHAVIORAL; Name: Self-directed program; Assigned to Arm(s): Self-Directed Program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telecommunication Enhanced Asthma Management
Brief Summary: The primary aim of this project is to conduct a randomized practical clinical trial within a large health maintenance organization to test a telephone intervention designed to improve adherence to daily asthma medications and thereby improve asthma outcomes. The investigators hypothesize that adherence with inhaled corticosteroid medications in the TEAM intervention group will be greater than in the usual care group.


Options:
A: Arm Label: Paper Asthma Action Plan; Type: EXPERIMENTAL; Interventions: Other: Paper Asthma Action Plan | Arm Label: Mobile Phone; Type: EXPERIMENTAL; Interventions: Device: Mobile Phone | Intervention Type: OTHER; Name: Paper Asthma Action Plan; Assigned to Arm(s): Paper Asthma Action Plan | Intervention Type: DEVICE; Name: Mobile Phone; Assigned to Arm(s): Mobile Phone
B: Arm Label: Tailored asthma management program; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored asthma management program | Arm Label: Generic web-based education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Generic web-based education | Intervention Type: BEHAVIORAL; Name: Tailored asthma management program; Assigned to Arm(s): Tailored asthma management program | Intervention Type: BEHAVIORAL; Name: Generic web-based education; Assigned to Arm(s): Generic web-based education
C: Arm Label: Speech recognition (TEAM intervention); Type: EXPERIMENTAL; Interventions: Behavioral: Speech recognition | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Speech recognition; Assigned to Arm(s): Speech recognition (TEAM intervention)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Web-based Asthma Management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Generic web-based asthma education | Intervention Type: BEHAVIORAL; Name: Tailored Web-based Asthma Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Generic web-based asthma education; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telecommunication Enhanced Asthma Management
Brief Summary: The primary aim of this project is to conduct a randomized practical clinical trial within a large health maintenance organization to test a telephone intervention designed to improve adherence to daily asthma medications and thereby improve asthma outcomes. The investigators hypothesize that adherence with inhaled corticosteroid medications in the TEAM intervention group will be greater than in the usual care group.


Options:
A: Arm Label: Speech recognition (TEAM intervention); Type: EXPERIMENTAL; Interventions: Behavioral: Speech recognition | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Speech recognition; Assigned to Arm(s): Speech recognition (TEAM intervention)
B: Arm Label: Case Group; Type: N/A; Interventions: N/A | Arm Label: Control Group; Type: N/A; Interventions: Other: MyMediHealth access | Intervention Type: OTHER; Name: MyMediHealth access; Assigned to Arm(s): Control Group
C: Intervention Type: PROCEDURE; Name: Written Action Plan for Acute Asthma; Assigned to Arm(s): N/A
D: Arm Label: Automated Phone-Based Refill Reminders; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Phone-Based Refill Reminders | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Automated Phone-Based Refill Reminders; Assigned to Arm(s): Automated Phone-Based Refill Reminders

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brazilian Intervention to Increase Evidence Usage in Practice - Acute Coronary Syndromes
Brief Summary: Phase 1: An observational study (registry) will be conducted which will objectively document the ACS clinical practice in Brazilian public hospitals, and identify the important barriers for the evidence usage incorporation in the clinical practice.

Phase 2: A Cluster randomized clinical trial in which public hospital will be randomized to receive or not a multifaceted strategy in order to increase evidence based therapy in clinical practice.


Options:
A: Arm Label: Quality improvement program; Type: OTHER; Interventions: Other: multifaceted strategy | Arm Label: Hospital standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: multifaceted strategy; Assigned to Arm(s): Quality improvement program
B: Intervention Type: PROCEDURE; Name: CT Scan; Assigned to Arm(s): N/A
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Reminder | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Reminder | Intervention Type: BEHAVIORAL; Name: Educational Reminder; Assigned to Arm(s): Control, Intervention
D: Arm Label: CARE; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheter Reminder and Evaluation Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Catheter Reminder and Evaluation Program; Assigned to Arm(s): CARE

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brazilian Intervention to Increase Evidence Usage in Practice - Acute Coronary Syndromes
Brief Summary: Phase 1: An observational study (registry) will be conducted which will objectively document the ACS clinical practice in Brazilian public hospitals, and identify the important barriers for the evidence usage incorporation in the clinical practice.

Phase 2: A Cluster randomized clinical trial in which public hospital will be randomized to receive or not a multifaceted strategy in order to increase evidence based therapy in clinical practice.


Options:
A: Intervention Type: BEHAVIORAL; Name: multifactorial continued educational - behavioural programme; Assigned to Arm(s): N/A
B: Arm Label: Quality improvement program; Type: OTHER; Interventions: Other: multifaceted strategy | Arm Label: Hospital standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: multifaceted strategy; Assigned to Arm(s): Quality improvement program
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Web Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: web intervention | Arm Label: Nurse Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: nurse intervention | Intervention Type: BEHAVIORAL; Name: web intervention; Assigned to Arm(s): Web Intervention | Intervention Type: BEHAVIORAL; Name: nurse intervention; Assigned to Arm(s): Nurse Intervention
D: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pseudo-randomised, Double-blinded Placebo-controlled Trial of Chloroquine or Sulphadoxine-pyrimethamine Alone or in Combination With Primaquine or Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Pakistan
Brief Summary: This study is an evaluation of the benefit of adding artesunate to existing first and second line antimalarial therapies in Pakistan.

A placebo controlled trial was carried out to assess two potential benefits of Artesunate Combination Therapy (ACT): efficacy and potential for transmission reduction.


Options:
A: Arm Label: CQ; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine (CQ) | Arm Label: CQ+PQ; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine (CQ), Drug: primaquine (PQ) | Arm Label: CQ + AS; Type: EXPERIMENTAL; Interventions: Drug: artesunate (AS), Drug: Chloroquine (CQ) | Arm Label: SP; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine (SP) | Arm Label: SP + PQ; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine (SP), Drug: primaquine (PQ) | Arm Label: SP + AS; Type: EXPERIMENTAL; Interventions: Drug: artesunate (AS), Drug: sulphadoxine-pyrimethamine (SP) | Intervention Type: DRUG; Name: artesunate (AS); Assigned to Arm(s): CQ + AS, SP + AS | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine (SP); Assigned to Arm(s): SP, SP + AS, SP + PQ | Intervention Type: DRUG; Name: Chloroquine (CQ); Assigned to Arm(s): CQ, CQ + AS, CQ+PQ | Intervention Type: DRUG; Name: primaquine (PQ); Assigned to Arm(s): CQ+PQ, SP + PQ
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
C: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)
D: Intervention Type: DRUG; Name: primaquine; Assigned to Arm(s): N/A

Answer: A